

RSPCA



What's happening with animal research in Europe? Successes and ongoing challenges

Animals in Science Department



Registered charity in England and Wales. Charity no. 219099.

RSPCA's PRINCIPAL GOAL: Champion the global replacement of animals in science with humane, New Approach Methodologies (NAMs)


Immediate aims:

- Challenge whether and how animals are used
- Reduce animal numbers and suffering, and improve welfare




What's happened over the last decade?

- Brexit
- Significant advances in NAMs
- Replacement Strategies
- Wider recognition of animal sentience
- Greater recognition of emotional labour
- Increased efforts to address issues with experimental design, conduct and reporting
- Development of AWB networks



Organoids




Organs-on-chips



Predictive modelling



Human tissues



EUROGROUP
FOR
ANIMALS

2022 SURVEY

Major users of animals
for scientific purposes in the

EU



6,131,243* animals used in research, testing and education



73%

I am **very concerned** about the use of animals in scientific research, testing, and education.



76%

More needs to be done to accelerate the full replacement of animal experiments.



77%

The European Commission and its Member States should develop a coordinated strategy to transition to scientific research, testing, and education **without the use of animals**.



75%

The European Union **should be a global leader** in moving towards science and innovation **without the use of animals**.

*Data for Belgium, Denmark, France, Germany, Italy, the Netherlands, Spain and Sweden from the [report on the statistics on the use of animals for scientific purposes in the Member States of the European Union and Norway in 2019](#)

Our top five priorities for lab animals

**Phase out
animal use**

**End
severe
suffering**

**Strengthen
laws and
regulation**

**Challenge
whether and
how animals
are used**

**Promote
animal welfare
worldwide**



**PHASING OUT
LAB ANIMALS**



**We want to reach a point where important science is done
without causing harms to animals**


The aim is to persuade governments, politicians, regulators, industry, scientists and other stakeholders that 'phasing out' the use of animals in science:

- is a **desirable goal**
- and to **commit to work to achieve this**

This includes putting in place **clear and co-ordinated strategies** for increasing the development, validation, and use of **New Approach Methodologies**



- **Non-Animal Technologies (NATs)**
- **Non-Animal Methods (NAMs)**
- **New Approach Methodologies (also NAMs)**



Animals in science

EU actions for the protection of animals used for scientific purposes

PAGE CONTENTS

[Overview](#)

[Objectives](#)

[Law](#)

[The “Three Rs”](#)


[EU networks](#)

[Implementation](#)

Overview

The protection and welfare of animals is a priority for the EU. This includes wildlife, zoo animals, farm animals, animals in transport and animals used for scientific purposes. Regarding animals in science, EU legislation is unique as it sets a final goal of full replacement of all animals used for scientific and educational purposes and is taking concrete action towards that goal.

Studies that still need to be carried out on animals must be done in compliance with specific regulations that aim to improve the welfare of those animals. This includes studies on increasing the basic understanding of human or animal biology, developing or producing new medicines, physiological studies, environmental effects or testing chemicals or new food additives.






Ethics and societal interest - public think more needs to be done to reduce the impacts of science on animals



Economics - animal research is expensive and there's increasing concerns about scientific limitations; the medicines development process is lengthy, costly and frequently involves late-stage failures - not sustainable



Technological advances - models being developed using human cells and tissues are advancing rapidly and raising ambitions for what is, and could be, possible

3D-printed tissue brings new realism to medical training

by University of Minnesota

edited by Gaby Clark, reviewed by Robert Egan

✓ Editors' notes





Image source: NIAID, Aedes Mosquito and Dengue Virus Particles, (CC BY 2.0)

News • Mechanopathology

'Dengue-on-a-chip' to study infection mechanisms

Researchers at Leiden University... mimics how...



Tissue Chips Accurately Model Organs in Space



... Astronaut Jessica Meri conducts cardiac research using tissue chip platforms in the Life Sciences Glovebox aboard space station in March of 2022. NASA


Scientific and technological progress

emulate GEN

WYSS INSTITUTE

Human Liver Chips are Better Predictors of Drug-Induced Liver Injury (DILI) than Animal Models

(Ewart et al. *Nat Rev Clin Oncol* 2021; led by Emulate, Inc.)



Charles River and Sanofi collab to replace animals with virtual controls in preclinical research

By Helen Floersh - Jun 5, 2024 5:40pm


Sanofi Charles River Laboratories contract research organizations animal testing



The idea behind virtual control groups is that because there are plenty of control data already from previous studies, data from treatment groups can simply be compared to that historical information. (Adobe Stock)

Neural organoids offer insight into mechanisms of dementia

Smo • 1 min read



Some areas of science will be more challenging

For example, studies:

- Investigating the working and diseases of the brain
- Trying to understand the function of different genes
- Requiring a complete and functioning immune system
- Assessing bioaccumulation, reproductive and chronic toxicity
- Involving wild animals looking at behaviour or interactions within complex ecosystems



Global non-animal testing market is growing

Global market for non-animal technologies = **\$29.4 billion** by 2030



Science Ticker
Apr 11, 2024 | Charles River Laboratories


Charles River Launches Alternative Model Project







Charles River Laboratories has announced the launch of the Alternative Methods Advancement Project (AMAP), which is a continuation of the company's investment in finding and researching alternatives to animal models wherever possible.

The initial investment of \$200 million will be bolstered with an additional \$300 million over the next five years to develop alternative methods. For example, the Endosafe® Trillum™ bacterial endotoxin test was developed to replace some of the need for blood-based testing, while also being compatible with existing instruments to reduce physical waste.



Dec 17, 2024 8:00 AM Eastern Standard Time

Merck to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio



Share      

- HUB internationally recognized pioneer in organoid development
- Acquisition expands Merck's 2D and 3D cell culture portfolio
- Organoids part of fastest growing cell culture segment; hold potential to speed up drug development, reduce animal testing



New approach methods (NAMs) and in vitro alternatives

Achieve your goals ethically and sustainably using the newest methods, technologies and alternatives.





Commission accelerates transition away from animal testing in chemical safety assessments

PAGE CONTENTS

Top

Quote(s)


Related topics

Print friendly pdf

Contacts for media

Today, the European Commission presented a **roadmap towards phasing out animal testing for chemical safety assessments**, which lays out clear, tangible steps to ensure the transition to innovative non-animal approaches. The roadmap will also preserve the integrity of safety evaluations, which ensure a high level of protection for human and animal health and the environment.

This initiative supports and strengthens the existing REACH framework, the EU's chemicals legislation, and is a concrete deliverable under the Chemicals Action Plan presented by the Commission in July 2025. With 22 actions under three pillars, the roadmap envisages **gradually replacing animal testing for chemical safety assessments** in 15 domains, including chemicals for industrial and consumer uses, pesticides and biocides, pharmaceuticals, and food and feed additives. The roadmap sets out indicators that will help to monitor progress in the implementation of the actions and recommendations.



The 3Rs in Horizon Europe

- Cluster 1 (Health): organoids, organs-on-chips, in silico toxicology, AI-based prediction, and human-relevant disease models
- Cluster 6 (Food, Bioeconomy, Natural Resources): animal-welfare innovation, refinement tools, and sustainable livestock systems
- European Partnerships:
 - Animal Health & Welfare Partnership (EUPAHW) – ~€360 million (2024–2030)
 - Agroecology Partnership – includes welfare and reduction-focused research
- Mission-oriented calls supporting NAMs for chemical safety, environmental health, and One Health




Commitments to phasing out animal use, including UK

Press release

Animal testing to be phased out faster as UK unveils roadmap for alternative methods

New plan backs researchers to seize on new and developing opportunities to phase out animal tests with specific commitments for the coming years.



£75m

November 2025



26 'actions'
with relevance across ALL
areas of animal use in
research and testing

basket 1



Animal testing for which alternative technologies have already been developed or which are not scientifically necessary

➔ **Implement Roadmap with Milestones**

basket 2



Animal testing for which there are concrete ideas and hypothesis for the development of alternative methods

➔ **Prioritization of R&D Efforts and Business Cases**

basket 3



Animal testing for which there is still no concept of how they can be replaced by animal-free methods: Greatest innovation potential

➔ **Evolution of Science and Blue Ocean Opportunities**

Investment priority: Replace

Investment priority: Refine




*"The Netherlands aims to become an international frontrunner in creating innovations that make animal testing obsolete. For this reason, the national government is encouraging the development and application of research methods that do not involve animal testing. This is being conducted through the partner programme **Transition Programme for Innovation without the use of animals.**"*

"TPI's partners are active in government, society, academia and the business community"

"The TPI partners want to accelerate the transition to animal-free innovation"

*In the statement, the Experimental Animals Committee recommends that an initiative be taken for a Norwegian public study (NOU) that can **map the potential for a transition to research without experimental animals, formulate clear objectives, and present a concrete plan for the transition.***



September 2020

Norway establishes a 3R Centre

The Norwegian Government has provided 6 million kroner (approx. 550,000 euros) in 2026 to start the work of establishing a national 3R Centre. This year, half of the money will be used by the Norwegian Veterinary Institute, in collaboration with experts in the field, to produce an overview of our knowledge today regarding the 3Rs and the resources available to implement them. The other half will be used by the Norwegian Food Safety Authority (NFSA, Mattilsynet) to start the work of establishing a Centre.



In 2027, the NFSA will receive 6 million kroner to run the Centre.

*“The establishment of a 3R center is therefore an important breakthrough. But without a **national roadmap for phasing out, with clear goals, deadlines and investments**, we risk the center becoming mostly symbolic.”*

*Anton Krag & Helle Haukvik,
Animal Welfare Alliance*


Barriers to replacing animals

Wider use of New Approach Methodologies is currently limited by:

Development: overcoming scientific and technological challenges

Acceptance: recognition of and confidence in NAMs by scientists, regulators of medicines, vaccines and chemicals etc, journal editors and reviewers

Uptake: awareness, knowledge and skills, willingness to move away from traditional approaches, access and availability



How the pharmaceutical industry is working to avoid and replace the use of animals for scientific purposes

An online event co-organised by EFPIA and the RSPCA

EFPIA Annual Conference

European Federation of Pharmaceutical Industries and Associations

Events < Previous

How the pharmaceutical industry is working to avoid and replace the use of animals for scientific purposes 22.06.23 REGISTER

Zoom

Members of EFPIA have committed to the science-based phase-in of methods to replace the use of animals for scientific purposes and the deletion of animal tests which are obsolete or redundant. EFPIA members aim to lead progress on this by engaging in a wide range of activities to help drive the development, uptake and promotion of non-animal technologies (NATs) and new approach methodologies (NAMs) so that these can be phased-in as soon as it is scientifically possible to do so.

During this free-to-attend webinar event, held on **Thursday 22 June 2023 (10:00-12:00 CET)** in conjunction with the Animals in Science team at the RSPCA - the UK's leading animal welfare organisation - participants will hear about practical steps that are being taken within the industry to avoid, replace and reduce animal use. We will highlight opportunities for making further progress, and discuss the challenges involved, providing examples of current work towards overcoming these. There will also be a presentation on "what does success look like?" which will identify potential key performance indicators to monitor progress with avoiding and replacing animal use.

Logos: SANOFI, MERCK, novo nordisk, RSPCA


Agenda and confirmed speakers

1:00	Welcome - Kirsty Reed, EFPIA & Barney Reed, RSPCA
1:05	EFPIA's vision, aims and activities - Kirsty Reed, EFPIA



ACTION PLAN FOR COMPANIES


to accelerate the transition to non-animal science in the pharmaceutical sector



eurogroupforanimals.org/library/action-plan-accelerate-transition-non-animal-science-pharmaceutical-sector

Supporting Replacement in Academia

Exploring barriers around the
acceptance and uptake of non-animal methods
in science in UK academia



Renelle McGlacken & Barney Reed
Animals in Science Department, RSPCA

September 2024

SUPPORTING THE REPLACEMENT OF ANIMALS IN ACADEMIA

Challenges to replacing animals in science not only include **technological** progress, but also **social**, **cultural**, and **economic** factors. These need to be addressed to ensure that non-animal approaches are used where they exist and to support their wider development and uptake in the future.

54%

of animal use for scientific
purposes in the UK takes
place in universities or
medical schools

Latest available data.
Source: Home Office 2020.

POTENTIAL CHALLENGES TO REPLACING ANIMALS IN ACADEMIA



Limited interaction across
scientific disciplines, and
between scientists within
and outside of academia



Researchers may develop skills,
status, and networks around
particular animal 'models' which
encourage their continued use



Perceptions that using
non-animal methods may
pose risks



Inefficient review
processes in assessing
Replacement
opportunities



Biases towards animal
methods in publishing
processes



Limited funding
encouraging research into,
and dissemination of, non-
animal methods



Limited education and
training involving non-
animal methods



Access to infrastructure and
resources needed to use non-
animal methods



Limited institutional
support and strategy
around Replacement

In academia

Cultures of 'doing science' currently lead to *inertia*

- Animal models taught as 'gold standard'
- 'Traditional' methods passed on
- Lack of 'value' placed on development and use of NAMs
- Insufficient inter-disciplinary collaboration
- Lack of support for changes in career direction



Our top five priorities for lab animals

Phase out
animal use

**End
severe
suffering**

Strengthen
laws and
regulation

Challenge
whether and
how animals
are used

Promote
animal welfare
worldwide



Our aim is to end severe suffering for animals in science

10% of animals used in experiments worldwide*



Around 1 million procedures within the UK and EU each year

+10 million animals across the world each year*

FOCUS ON SEVERE SUFFERING

“Any level of suffering is obviously a concern for everyone, but tackling severe suffering should be a top priority.”

Dr Penny Hawkins, RSPCA




Causes of severe suffering

1. **Some procedures** are likely to cause severe suffering in themselves (e.g. if they are to study painful diseases in humans or other animals)
2. A combination of less severe factors can lead to increased overall suffering: '**cumulative severity**'
3. Where **animals die**, this may involve severe suffering – including both unexpected mortality, and 'death as an endpoint'



Website with Roadmap

Roadmap steps




Expert working groups


REPORTS

 Avoiding mortality	 Experimental Autoimmune Encephalomyelitis (EAE)	 Rheumatoid arthritis	 Seizures, convulsions and epilepsy
 Sepsis	 Spinal cord injury	 Cardiovascular research	 Neuropathic pain


UK and international meetings







Bone marrow ablation and reconstitution in mice



focusonseveresuffering.co.uk/causes/reports

International Focus on Severe Suffering events


2026	Spain
2025	Greece (within FELASA)
2024	France
2023	Netherlands
2022	Sweden
2019	Greece
2017	Germany
2016	Belgium



Progress so far - UK

68%
reduction


in experimental procedures causing severe suffering in the UK since 2014



Progress so far - EU and Norway

33%
reduction

In the EU and Norway,
8.7% of procedures were
classified as severe in
2023



How this was achieved

Experimental design

- Earlier scientific and humane endpoints
- Better screening of animals and strain selection
- Use of animals at earlier disease stages
- Better husbandry and support
- Use of technology

Cultural factors

- Better communication within teams, more project review meetings, analysis of records
- More involvement of animal technologists, especially around identifying clinical signs*
- AW(ER)B involvement


*Building bridges: Involvement of animal care staff and laboratory technicians in experimental planning and conduct of animal studies for better job satisfaction and science ([here](#))

Challenges

- Mice used for monoclonal antibody production via the ascites method
- Fishes used for batch potency testing
- Fishes used for studies on the immune system
- Fishes used for acute toxicity testing
- Rodents used for studies on human immune disorders
- Rodents used for LD50/LC50 testing


Translational and applied research uses

source : alures published data



Norway 2023

- 46,000 severe procedures
- 96.6% of these on salmon, trout, char and grayling
- Of these, 74% are for animal diseases and disorders
- 15% for batch potency testing



Fishes in acute toxicity testing - 2023 humane endpoints meeting (UK)

- Define and implement a standardised approach to **identify sub-lethal clinical signs** and apply humane endpoints
- Establish standardised approaches to **staff training on identifying clinical signs** and education in fish behaviour and welfare
- Promote collaboration and information-sharing networks within the scientific community to facilitate the **generation and dissemination of resources**




NC3Rs

Retrospective Assessment

- Has the work been carried out?
- Were the objectives achieved?
- How much harm was caused to the animals?
- What 3Rs lessons are there?

Outcomes:

- Feedback to research group
- Dissemination of 3Rs lessons - positives and negatives, internally and externally
- Updates for Non-Technical Summaries
- Review effectiveness of project evaluation, training



Retrospective Assessment (RA) challenges



- FELASA workshop 2025
 - Confusion as to what RA actually is
 - Overwhelming need for better training (especially for researchers)
 - Need for feedback on RAs that are submitted
- Not all countries update NTSs (ALURES)
 - Belgium, Bulgaria, Greece, Croatia, Cyprus, Lithuania, Netherlands, Norway, Austria, Poland, Portugal, Romania, Slovenia, Slovakia, Sweden, Finland
- Issues with technical language ...

Gemini on UK RA updates:

This document is **not easy to understand** for a general audience. While it is labelled as 'non-technical summaries,' a significant amount of **specialised scientific and medical terminology** is used throughout. A background in biology, medicine, or a related field is necessary to fully comprehend the content.

In some cases, the researchers **do explain** how they plan to share the advances they have made in the 3Rs. However, the **level of detail and the methods of sharing vary** between the different project summaries.

Our top five priorities for lab animals

**Phase out
animal use**

**End
severe
suffering**

**Strengthen
laws and
regulation**

**Challenge
whether and
how animals
are used**

**Promote
animal welfare
worldwide**



Our vision for AWBs and similar bodies

- Every AWB is **well-resourced, supported, valued** and **effectively challenges** whether and how animals are used
- They **fulfill all their tasks** including promoting all **3Rs**, providing **robust ethical advice** and developing a **good culture of care**
- Each one is committed to **minimising suffering** and **maximising welfare** across animals' lives



Top 5 operational challenges


1. Lack of recognition and reward for AW(ER)B members
2. Lack of training and Continuing Professional Development (CPD) for members
3. **Insufficient time** for all those directly and indirectly involved
4. Need for 'professionalisation' of the AW(ER)B (including career progression)
5. Lack of liaison with Research Integrity Committees and similar bodies

Strengthening AWERBs: Resource, Engagement, and Recognition



AWERB-UK 2025 Meeting Summary Report

Ellie Muscat & Penny Hawkins
Animals in Science Department



Culture of care in animal research - The International Culture of Care Network

Thomas Bertelsen, Novo Nordisk A/S, Denmark; Adrian Smith, Norecopa, Norway and members of The International Culture of Care Network

Background

The EU working document on Animal Welfare Bodies and National Committees states:

- Ensuring an appropriate culture of care is in everyone's interests, as it will promote improved animal welfare.
- Simply having animal facilities and resources which meet the requirements of the legislation will not ensure that appropriate animal welfare, care and use practices will automatically follow.

The aims of the Culture of Care Network

To provide a forum for the quick and efficient dissemination of ideas and efforts to create a culture of care

- To promote a mindset and behaviour that continuously and proactively works to advance laboratory animal welfare and the 3Rs.
- To aim for more than a culture of compliance.
- To encourage a culture of challenge, rather than accepting established practice.

Interested in joining?

As a member, you are expected to work actively with culture of care.

Please write to: CultureOfCareNetwork@gmail.com



Our members

The Network consists of people with a large range of backgrounds:

- Laboratory animal scientists & technicians
- Laboratory animal veterinarians
- Members of Animal Welfare Bodies
- Representatives of National competent authorities
- Communications experts
- Members of animal welfare organisations

This diversity of competency and perspectives ensures that the network encourages a culture of care both for the animals used in research and for those working with them.

We are currently 38 members in 16 countries.



norecopa.no/CoC

References:

- The legal framework for a culture of care: https://ec.europa.eu/environment/chemicals/lab_animals/pdf endorsed_awb-nc.pdf
- A Quick Start Guide: <https://norecopa.no/CoC/quick-start-guide>
- An overview of culture of care resources: <https://norecopa.no/CoC/resources>





A voluntary network of European
3R Centres dedicated to advancing
the 3Rs in biomedical science
... but some Centres are currently under
threat



Experimental design, conduct and reporting

- PREPARE (now with specific guidance for fish researchers)
- ARRIVE
- Experimental Design Assistant
- Sex Inclusive Research Framework (SIRF)
- DRIVER (*in vitro*)







Scan for more information



Zebrafish enrichment Natural environment



Wild zebrafish are found in habitats with a variety of vegetation, substrates and water flow rates.

Better for science... better for animal welfare

Royal Society for the Prevention of Cruelty to Animals
©2001-2020 RSPCA animals.org.uk
We exist to inspire everyone to create a better world for every animal.
The RSPCA helps animals in England and Wales. Registered charity no. 2110099. The RSPCA only exists with the support of public donations.
Copyright ©RSPCA 2020. All rights reserved. This material must not be reproduced or used in any manner whatsoever without the express written permission of the RSPCA.

Refined methods of DNA collection in fishes

Aim of this resource

To help AWERBs discuss good practice for collecting DNA samples for genotyping from small laboratory fishes.

Relevant AWERB task


Advising staff on animal welfare and the application of the 3Rs.

Recommendation

Review current practices and discuss DNA collection techniques and training, as well as issues around different sampling methods. The most refined method is being used.

The Issue

DNA samples for genotyping small laboratory fishes such as zebrafish are frequently collected by fin clipping – removing a small portion of (tail) fin. However, this process is invasive and painful, and also fish to be handled, which can be stressful. There are a number of sampling techniques available which should be reviewed by the AWERB to ensure the most refined method is used.



rspca.org.uk/awerb

Environmental enrichment for zebrafish

Aim of this resource

To help AWERBs discuss local practice for providing laboratory zebrafish with environmental enrichment.

Relevant AWERB task

Advising staff on animal welfare and the application of the 3Rs; supporting named persons and others dealing with animals.

Recommendation

Regularly review and discuss different forms of environmental enrichment that can be provided to laboratory zebrafish.



The Issue

Zebrafish used in scientific research tend to be provided with relatively little environmental enrichment. This may be in part due to a belief that zebrafish do not benefit from enrichment. However, there is now plenty of evidence that providing enrichment can reduce stress and improve welfare in zebrafish. This sheet can be used as a resource to stimulate discussion of different forms of enrichment which can be provided to zebrafish.

science.rspca.org.uk/researchanimals/reportsandresources/housing

Focus on Fish



For updates about all our meetings:
science.rspca.org.uk/utilities/newsletter

11:00	Welcome
Session 1	
11:05	Fish cognition, sentience and welfare
11:30	Welfare effects of early-life enrichment in Atlantic salmon used in research
11:55	Influence of environmental enrichment in the husbandry environment on the results of an applied fish behavioural study
12:20 - 1:15	Break
Session 2	
1:15	Not deadly, but troublesome: addressing common fish discomforts
1:40	Assessing vitality and fitness for release in wild-caught species
2:05	An alternative approach to minimising harms
2:30 - 2:50	Break
Session 3	
2:50	Breeding Strategies and Genetic Integrity in Zebrafish Colonies
3:15	Lighting in the zebrafish facility
3:40	Facility design and management: maximising fish welfare
4:05-4:15	Take home messages, wrap up and close

Refining Basket 3 - wild animal use

- Non-lethal sampling
- *Ex vivo* studies (e.g. animals found dead)
- Environmental DNA sampling
- Refinements in biotelemetry devices
- Recognition of potential harms to non-target animals and species




Looking to the future ...



Drivers of animal use

- Climate change
- Air and plastic pollution
- Ageing populations
- Chronic diseases
- Future pandemics
- Antimicrobial resistance
- Geopolitical upheaval
 - Animal models of injury and trauma
 - Challenges to ethical decision-making




Replacement strategy risks

- '3Rs-washing' - *in vitro* models are presented as replacements when they are being developed in their own right and not replacing animal use at all
- **Lack of strategic thinking** around the focus for Replacement, e.g. lack of focus on:
 - models that cause most suffering
 - areas where the uptake of alternative approaches has been slow (e.g. non-animal derived antibodies)
 - ensuring collaboration between industry and academia
 - ensuring good standards for *in vitro* research (DRIVER)



Transitioning away from animal use should be integrated into the Culture of Care

- Transitioning to NAMs involves processes that will take place over many years
- Animal technologists, scientists, vets and all involved:
 - Support opportunities for reducing harms to animals
 - Understand that science continually evolves and that new models and technologies continually emerge
 - Want opportunities for career development in science
- - but in some cases this will involve significant change as NAMs progressively replace animals





Institute of
Animal
Technology



Sociedad Española
para las Ciencias del
Animal de
Laboratorio



DALAS

Dutch Association for
Laboratory Animal Science

Dutch Association for
Laboratory Animal
Science



Association Française
des Sciences et
Techniques de L'Animal
de Laboratoire




GV-SOLAS

Gesellschaft für Versuchstierkunde
Society for Laboratory Animal Science


Harnessing technology, e.g. AI and Home Cage Monitoring

- AI can be used in drug discovery, disease classification and biomarker identification
- Machine learning models can predict drug toxicity and efficacy before animal testing, avoiding some animal use
- Some companies are attempting to use data sets and AI for drug discovery without animals
- Home Cage Monitoring technology (which may also use AI) enables better surveillance and reduces human observer bias



Negative aspects of AI

- It has been suggested that AI has been misused in research fraud, contributing to the reproducibility crisis
- AI could accelerate biomedical research by identifying many more candidate compounds, expanding animal use in the current climate
- Risk of project design or ethical review by AI, removing incentives and opportunities to challenge and reflect



Greater understanding of animal sentience

- **'Feelings that matter to the animal'**
- Acts as a driver for all 3Rs
- Challenges use of 'lower' animals as 'Replacements'
- Should lead to application of precautionary principle regarding the scope of legislation and regulations relating to animals
 - UK Animal Sentience Act 2022



Globalisation of research and testing

Positives	Negatives
<ul style="list-style-type: none">• Can act as a driver to improve standards• Opportunities to share knowledge and expertise and 'level up'• ICLAS Special Working Group is leading work, collaborating with a range of regional and global LAS-related organisations, to develop guidelines on globally harmonised standards in key areas relevant to scientific quality, animal welfare and ethical oversight	<ul style="list-style-type: none">• Some countries are expanding biomedical research but not investing in good quality animal care and use• Many countries have low standards around implementing the 3Rs, regulation, enforcement, and ethical review• Some countries are investing in significant new animal breeding infrastructure as 'national assets' e.g. a new NHP breeding facility in France to house 1,800 primates (opposed by 93% in a public consultation)• Lack of harmonisation of good animal care and welfare standards

Where might Europe be in 2036? A vision ...

- Ambitious **phase-out strategies** established by countries, organisations and companies are well-supported and are being successfully implemented
- **NAMs are dominant**, with animal use reduced to a smaller number of challenging areas
- Animal technologists and scientists are **transitioning in step with strategies**
- **Data assets and AI** are being used to create models and generate insights, whilst avoiding or reducing animal use
- **Global harmonisation** between regulatory bodies accelerates the acceptance and uptake of NAMs and eliminates duplication
- Research funding bodies **increase scrutiny** of animal use, emphasising **outcomes and impact**
- The **reproducibility crisis** is over
- No animal experiences **severe suffering**
- Greater openness leads to more robust **harm-benefit analysis and ethical review**, driven by **public expectations**

GLOBAL HARMONISATION ACHIEVED:
ICH/OECD/EMA UNIFIED REGULATIONS FOR NAMs

RESEARCH FUNDING 2036:
FUNDING PRIORITIZES NAMs & MIPACT

**REPRODUCIBILITY
CRISIS RESOLVED:**
ROBUST DATA SHARING

**LEADING THE WAY IN HUMANE,
EFFECTIVE SCIENCE 2036**



**AI-DRIVEN REPLACEMENT MODELS:
PREDICTIVE TOXICITY (99% ACCURACY)**

**ELIMINATING ANIMAL USE
IN DAFTT ASSESSMENT**

The central part of the image shows a group of scientists in white lab coats working at a lab bench. They are using various organ-on-a-chip models, including:

- HuHeart Chip**: A heart model on a chip.
- Liver-on-a-Chip**: A liver model on a chip.
- NeuroSpheroid**: A brain spheroid model on a chip.

There are also beakers with colored liquids and other lab equipment on the bench. The scientists are looking at tablets and monitors, discussing their work.





rspca.org.uk/animalsinscience



linkedin.com/in/rspca-animals-in-science



animalsinscience@rspca.org.uk

